Alaunos Therapeutics (NASDAQ:TCRT) & Sandoz Group (OTCMKTS:SDZNY) Critical Contrast

Sandoz Group (OTCMKTS:SDZNY) and Alaunos Therapeutics (NASDAQ:TCRT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Risk and Volatility

Sandoz Group has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of Sandoz Group shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sandoz Group and Alaunos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Alaunos Therapeutics	N/A	-168.02%	-121.37%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Sandoz Group and Alaunos Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	3	0	0	2.00
Alaunos Therapeutics	1	0	0	0	1.00

Valuation and Earnings

This table compares Sandoz Group and Alaunos Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$10.36 billion	2.48	$1.00 million	N/A	N/A
Alaunos Therapeutics	$10,000.00	565.76	-$4.68 million	($2.46)	-1.04

Sandoz Group has higher revenue and earnings than Alaunos Therapeutics.

Summary

Sandoz Group beats Alaunos Therapeutics on 6 of the 9 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.